Zura Bio stock heads into Piper Sandler meeting with losses widening

Published on 10/04/2026 at 23:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zura Bio stock was last at USD 4.11 on October 2 after a 0.72 percent decline. Phase 2 enrollment and a USD 19.75 consensus target shape the setup.

ZURA, KYG9TY5A1016, Illustration mit AI erstellt.

Zura Bio (ISIN KYG9TY5A1016) was last at USD 4.11 on Nasdaq on October 2, 2026, down 0.72 percent from USD 4.14. The clinical-stage biotech now heads into a virtual Piper Sandler meeting scheduled for October 5, 2026, while investors weigh trial execution against widening losses.

Phase 2 enrollment sets the catalyst

According to Yahoo Finance on September 11, 2026, Zura Bio completed enrollment in the TibuSHIELD Phase 2 study with 247 participants, above its original target. The TibuSURE study in systemic sclerosis enrolled 91 participants, also above its original target, with topline data expected in the first half of 2027.

The company is testing tibulizumab, also called ZB-106, in inflammatory and immune-mediated diseases. Yahoo Finance reported that Zura Bio plans to begin its NEXUS-PMR study for polymyalgia rheumatica by the end of 2026, adding a third indication to the lead program.

Losses rise as trials advance

The operating progress carries a higher financial cost. For the quarter ending June 30, 2026, Zura Bio reported a GAAP net loss of USD 26.3 million, compared with USD 15.99 million in the same quarter a year earlier, according to Yahoo Finance. GAAP loss per share was USD 0.21, compared with USD 0.17 a year earlier.

Cash and equivalents stood at USD 205.1 million on June 30, 2026. Research and development spending reached USD 20.7 million in the quarter, compared with USD 8.7 million a year earlier, showing how quickly the Phase 2 portfolio is consuming resources.

Consensus target stays far above price

Leerink Partners reiterated a Buy rating and an USD 11.00 price target on October 2, 2026, according to Markets Insider. The same report listed a Strong Buy consensus with an average price target of USD 19.75, putting that target 380.78 percent above the USD 4.11 price.

Guggenheim also reiterated Buy with a USD 20.00 target on October 2, 2026, while its published consensus target was USD 22.67, as Markets Insider reported. The gap between market price and analyst targets leaves the upcoming clinical readouts as the central test for the valuation.

Zura Bio stock remains below yearly high

Zura Bio was last at USD 4.11 on Nasdaq on October 2, 2026, with a market capitalization of USD 390.4 million and volume of 2,954,782 shares. The stock stood 44.76 percent below its 52-week high of USD 7.44 and above its 52-week low of USD 3.15.